Clinical Trial Update: Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 trial updating the biological activity and safety of low-dose interleukin-2 in relapsing multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Interleukin-2 (interleukin-2)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Relapsing Remitting Multiple Sclerosis | Phase 2 | Status: COMPLETED